In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase

Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: MENG, FANKAI, ZENG, WEN, HUANG, LIFANG, QIN, SHUANG, MIAO, NINGNING, SUN, HANYING, LI, CHUNRUI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919897/
https://www.ncbi.nlm.nih.gov/pubmed/24527087
http://dx.doi.org/10.3892/ol.2014.1780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919897/
https://www.ncbi.nlm.nih.gov/pubmed/24527087
http://dx.doi.org/10.3892/ol.2014.1780

Ejemplares similares